GlassScriptPhysician profile
Amardeep S Aulakh
NPI 1700047180
$64,787.58
in general payments reported to CMS, 2019-2025
67 companies · $9,882 in 2025
The $9,882 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,354 · 2020: $3,186 · 2021: $8,440 · 2022: $25K · 2023: $7,380 · 2024: $7,587 · 2025: $9,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $4,760 · Honoraria: $3,358 · Travel and Lodging: $1,807 · Education: $234 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,525.00 |
| Food and Beverage | $4,759.51 |
| Honoraria | $3,357.50 |
| Travel and Lodging | $1,807.27 |
| Education | $233.77 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24,167.40 | 2020-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $11,574.94 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Exelixis INC. | $5,586.83 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $3,512.67 | 2019-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $2,352.80 | 2020-2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $2,100.99 | 2019-2025 | |
| Celgene Corporation | $2,076.87 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Genzyme Corporation | $2,059.45 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $1,279.40 | 2019-2025 | Opdivo |
| Epizyme, INC. | $1,267.95 | 2021 | |
| Seagen INC. | $1,207.14 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $1,170.00 | 2022 | |
| Eisai INC. | $970.09 | 2020-2024 | |
| Glaxosmithkline, LLC. | $728.81 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $365.38 | 2019-2022 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.44 | 2020-2025 | Venclexta |
| Corcept Therapeutics | $290.82 | 2025 | |
| Alexion Pharmaceuticals, INC. | $284.27 | 2019-2023 | Ultomiris |
| Kite Pharma, INC. | $201.43 | 2019-2023 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $198.45 | 2021-2023 | Epkinly, Imbruvica |
| Janssen Biotech, INC. | $177.37 | 2019-2025 | Imbruvica, Tecvayli, Darzalex |
| Incyte Corporation | $177.06 | 2019-2023 | Jakafi, Pemazyre, Monjuvi |
| Sobi, INC | $175.07 | 2022-2025 | |
| Sirtex Medical INC | $169.42 | 2019-2024 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $155.97 | 2021-2025 | Onivyde, Tazverik |
| Cardinal Health 108 LLC | $152.49 | 2019 | |
| Merck Sharp & Dohme LLC | $151.84 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $144.99 | 2019-2023 | Tecentriq |
| Springworks Therapeutics, INC. | $139.07 | 2024-2025 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $134.52 | 2021-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $131.68 | 2019-2024 | Iclusig, Fruzaqla |
| Beigene USA, INC. | $102.36 | 2021-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $90.12 | 2023-2025 | Besremi |
| Lilly USA, LLC | $85.52 | 2023-2025 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $83.90 | 2019 | |
| Dova Pharmaceuticals | $69.23 | 2019-2021 | |
| Astellas Pharma US INC | $64.99 | 2020 | |
| Pfizer INC. | $61.75 | 2019-2024 | |
| Emd Serono, INC. | $57.03 | 2019-2022 | |
| Octapharma USA, INC. | $45.45 | 2025 | Octagam Immune Globulin (Human) |
| Genmab U.S., INC. | $45.05 | 2023-2025 | Epkinly |
| G1 Therapeutics, INC. | $44.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.09 | 2019-2025 | |
| Tempus Ai, INC | $28.17 | 2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $27.52 | 2021-2024 | Pyrukynd |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Vertos Medical, INC. | $21.19 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $20.96 | 2025 | Sancuso |
| Morphosys, US INC. | $20.26 | 2021 | |
| Novocure INC. | $17.51 | 2025 | Optune Lua (Novottf-200t) |
| Telix Pharmaceuticals | $17.10 | 2025 | Illuccix |
| Stemline Therapeutics INC. | $16.36 | 2023 | Orserdu |
| Shire North American Group INC | $15.76 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.33 | 2023 | Monoferric |
| Apellis Pharmaceuticals, INC. | $15.16 | 2023 | |
| Heron Therapeutics, INC. | $15.15 | 2022 | |
| Puma Biotechnology, INC. | $15.03 | 2021 | |
| Tesaro, INC. | $14.88 | 2019 | |
| Taiho Oncology, INC. | $14.87 | 2021 | |
| Deciphera Pharmaceuticals INC. | $14.26 | 2021 | |
| Servier Pharmaceuticals LLC | $14.05 | 2024 | |
| Kyowa Kirin, INC. | $13.67 | 2019 | |
| Secura Bio, INC. | $12.58 | 2021 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Iovance Biotherapeutics, INC. | $10.65 | 2025 | Amtagvi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amardeep Aulakh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.